Acquirer · Corporate
Foundation Medicine
1$595m$595m0
Image: SAGA DiagnosticsRoche's Foundation Medicine agrees to buy SAGA Diagnostics for up to $595 million
The Lund University spin-out sells Pathlight, a blood test for leftover cancer that Medicare already covers for early-stage breast cancer. Its main 2021 funding round was about $12 million.
$595m$17.6mStage n/aCorporate
Latest in Foundation Medicine
All Foundation Medicine exitsOpen tracker →
Foundation Medicine → SAGA Diagnostics$595m$250m–1bn